drugset / Trial / NCT00284973
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
Phase 1
Completed
70 enrolled
Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
PATH · collabSecond Military Medical University · collabWorld Health Organization · collabXinhua Hospital, Shanghai Jiao Tong University School of Medicine · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720. This trial is designed to test the safety and immunogenicity of 3 doses and 2 vaccination schedules. This blood stage candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas.
Timeline
- Start
- 2006-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PfCP2.9 | Vaccine | — | — |
| Background | Montanide ISA 720 | Unknown | — | — |